Azar Burak
Steatotic liver disease, commonly known as fatty liver disease, is a condition characterized by excess fat accumulation in the liver. It is often associated with metabolic syndrome, obesity, and type 2 diabetes. There are two primary forms: alcoholic fatty liver disease and non-alcoholic fatty liver disease. Recently, the potential of testosterone replacement therapy to improve steatotic liver disease has garnered significant attention. The primary risk factors for NAFLD include obesity, insulin resistance, hypertension, and dyslipidemia. The pathogenesis of steatotic liver disease involves complex interactions between metabolic, genetic, and environmental factors. Testosterone, a key male sex hormone, plays a vital role in various bodily functions, including muscle mass maintenance, fat distribution, and metabolism. Low testosterone levels, or hypogonadism, have been linked to an increased risk of metabolic syndrome and type 2 diabetes, conditions closely associated with NAFLD.
Comparte este artículo